A retrospective comparison of phototherapy need in O-B versus O-A incompatibility in a single Saudi institution

J Neonatal Perinatal Med. 2023;16(2):311-317. doi: 10.3233/NPM-221136.

Abstract

Background: ABO incompatibility is a major risk factor for neonatal indirect hyperbilirubinemia (NIH), requiring treatment. It has been shown that there are racial differences in direct antiglobulin test (DAT) positivity and phototherapy need in the O--B versus (vs) O--A incompatibility. The comparison between the O--B and O--A incompatibility is not well studied in Saudi Arabia.

Aims: We aimed to compare DAT positivity and phototherapy need in O-B vs O-A incompatibility in Saudi Arabia.

Methods: This retrospective cohort study was conducted in one Saudi hospital. We included a convenience sample of neonates born between 01 January 2013 and 31 December 2021. We included healthy neonates admitted to the nursery care unit only, born at≥38 weeks gestation, and had normal G6PD levels. Neonates that had no G6PD level measurement or lost follow-up post-discharge were excluded. The data span was the first 14 days of life.

Results: A total of 611 neonates met our inclusion criteria. Positive DAT was more prevalent in the O-B than the O-A incompatibility [43.5% vs 29.2%, p < 0.001). A greater odd of phototherapy need was observed in the O--B vs O-A incompatibility across various strata. Readmission for NIH, use of 360° exposure phototherapy, or intravenous immunoglobulin administration was more prevalent in the O-B than the O-A incompatibility (13.2% vs 5.0%, p < 0.001). A logistic regression analysis revealed that the O-B incompatibility modified the association between DAT positivity and phototherapy need.

Conclusions: The O-B incompatibility had a mediator effect on the relationship between DAT positivity and the need for phototherapy in the study population, which emphasizes that the O-B and O-A are not the same from the NIH point of view.

Keywords: ABO incompatibility; ABO isoimmunization; direct antiglobulin test; neonatal hyperbilirubinemia; phototherapy.

MeSH terms

  • ABO Blood-Group System
  • Aftercare*
  • Humans
  • Hyperbilirubinemia, Neonatal* / etiology
  • Hyperbilirubinemia, Neonatal* / therapy
  • Infant, Newborn
  • Patient Discharge
  • Phototherapy / adverse effects
  • Retrospective Studies
  • Saudi Arabia

Substances

  • ABO Blood-Group System